MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-09-2023
Aravive Long Term Debt Current 2011-2026 | ARAV
Annual Long Term Debt Current Aravive
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.2 M | 2.3 M | 2.09 M | 2.39 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.39 M | 2.09 M | 2.24 M |
Long Term Debt Current of other stocks in the Biotechnology industry
| Issuer | Long Term Debt Current | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aptorum Group Limited
APM
|
433 K | $ 1.06 | -0.93 % | $ 5.78 M |  China |
 |
Ascendis Pharma A/S
ASND
|
14.2 M | $ 201.94 | -3.26 % | $ 5 B |  Danmark |
 |
Autolus Therapeutics plc
AUTL
|
5.05 M | $ 1.82 | -4.85 % | $ 464 M |  Britain |
 |
Adagene
ADAG
|
1.18 M | $ 1.65 | - | $ 92.9 M | China |
 |
Alterity Therapeutics Limited
ATHE
|
57.6 K | $ 3.45 | 3.6 % | $ 8.3 B |  Australia |
 |
Arrowhead Pharmaceuticals
ARWR
|
7.29 M | $ 64.9 | -0.15 % | $ 8.68 B |  USA |
 |
AgeX Therapeutics
AGE
|
428 K | - | -10.17 % | $ 12.2 K | USA |
 |
Biogen
BIIB
|
86.4 M | $ 187.4 | 0.75 % | $ 27.3 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | USA |
 |
Albireo Pharma
ALBO
|
3.08 M | - | -0.23 % | $ 916 M | USA |
 |
Alpine Immune Sciences
ALPN
|
756 K | - | - | $ 2.17 B | USA |
 |
BioXcel Therapeutics
BTAI
|
374 K | $ 1.98 | -1.0 % | $ 5.02 M | USA |
 |
AlloVir
ALVR
|
10.8 M | - | 4.14 % | $ 49.1 M | USA |
 |
CASI Pharmaceuticals
CASI
|
1.06 M | $ 1.04 | -2.34 % | $ 142 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
274 K | - | -11.43 % | $ 502 K | USA |
 |
Catalyst Biosciences
CBIO
|
210 K | $ 10.74 | -2.1 % | $ 707 M | USA |
 |
Applied Molecular Transport
AMTI
|
4.64 M | - | - | $ 10.1 M | USA |
 |
Athersys
ATHX
|
1.01 M | - | 3.77 % | $ 22.4 M | USA |
 |
AIkido Pharma
AIKI
|
410 K | - | 1.93 % | $ 17.4 M | USA |
 |
Celldex Therapeutics
CLDX
|
1.45 M | $ 27.0 | -1.28 % | $ 1.74 M | USA |
 |
Cellectis S.A.
CLLS
|
8.38 M | $ 4.42 | -1.34 % | $ 116 M |  France |
 |
BioVie
BIVI
|
74.5 K | $ 1.27 | -2.31 % | $ 1.88 M | USA |
 |
ARCA biopharma
ABIO
|
213 K | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
75 K | - | 4.01 % | $ 150 M |  Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
5.38 M | - | -15.15 % | $ 60.3 M | Britain |
 |
BioNTech SE
BNTX
|
39.5 M | $ 99.81 | 0.97 % | $ 27.2 B | Germany |
 |
AVROBIO
AVRO
|
878 K | - | 1083.1 % | $ 745 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
6.8 M | $ 27.75 | 0.02 % | $ 1.34 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
43 K | $ 4.14 | -3.72 % | $ 9.01 B |  Israel |
 |
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
104 K | - | 2.71 % | $ 14 M | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
675 K | $ 11.13 | -2.02 % | $ 720 M | USA |
 |
Axon Enterprise
AXON
|
9.45 M | $ 633.45 | 3.34 % | $ 48 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
137 K | $ 2.64 | -0.75 % | $ 16.6 M | USA |
 |
BeiGene, Ltd.
BGNE
|
17.6 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
AstraZeneca PLC
AZN
|
339 M | $ 94.65 | 0.68 % | $ 96.9 B | Britain |
 |
Bellicum Pharmaceuticals
BLCM
|
11 M | - | -9.72 % | $ 5.89 M | USA |
 |
Acorda Therapeutics
ACOR
|
1.59 M | - | -24.86 % | $ 820 K | USA |